Thalomid and Revlimid
Thalomid and Revlimid Antitrust Litigation
Block & Leviton has filed suit against Celgene Corporation for the illegal monopolization and restrain of trade in the market for thalidomide (sold under the brand name Thalomid) and lenalidomide (sold under the brand name Revlimid), both of which are used to treat multiple myeloma, among other illnesses. The firm was recently appointed Co-Lead Counsel on behalf of a proposed class of end users and third party payers who purchased or provided reimbursement for Thalomid or Revlimid. The Complaint asserts that Celgene's anticompetitive conduct included: (1) using the Thalomid and Revlimid REMS programs, which are intended to ensure safe access to Thalomid and Revlimid, as a pretext to block generic entry; (2) fraudulently obtaining use patents on the procedures that ensure safe use of Thalomid and Revlimid; (3) engaging in sham litigation against any potential competitor who was able to obtain samples of Thalomid and Revlimid for use in bioequivalence testing; and (4) abusing the Citizen Petition process. We believe Celgene's acts have prevented any generic manufacturer from bringing less-expensive, generic versions of either Thalomid or Revlimid to market. The court denied Celgene's motion to dismiss the complaint on October 29, 2015. Discovery is currently underway.
If you have information about this case, or would like to receive a copy of the most current complaint, please contact Whitney Street by email at firstname.lastname@example.org or (415) 968-1852. Confidentiality to whistleblowers is assured.